The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
Patients with BRCA mutations often face aggressive disease and poor prognosis
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
Subscribe To Our Newsletter & Stay Updated
